Literature DB >> 11196310

Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines.

C Gottstein1, W Wels, B Ober, P E Thorpe.   

Abstract

Vascular targeting agents (VTAs) can be produced by linking antibodies or antibody fragments directed against endothelial cell markers to effector moieties. So far, it has been necessary to produce the components of VTAs (antibody, antibody fragment, linker, and effector) separately and, subsequently, to conjugate them by biochemical reactions. We devised a cloning and expression system to allow rapid generation of recombinant VTAs from hybridoma cell lines. The VTAs consist of a single chain Fv antibody fragment as a targeting moiety and either truncated Pseudomonas exotoxin (resulting in immunotoxins) or truncated human tissue factor (resulting in coaguligands) as effectors. The system was applied to generate recombinant immunotoxins and coaguligands directed against endoglin, vascular endothelial growth factor (VEGF):VEGF receptor (VEGFR) complex and vascular cell adhesion molecule 1 (VCAM-1). The fusion proteins exhibited similar functional activity to analogous biochemical constructs. This is the first report to describe the generation and characterization of recombinant coaguligands.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196310     DOI: 10.2144/01301dd03

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  4 in total

1.  Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.

Authors:  Bi-Sen Ding; Claudia Gottstein; Andrea Grunow; Alice Kuo; Kumkum Ganguly; Steven M Albelda; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

2.  Molecular engineering of high affinity single-chain antibody fragment for endothelial targeting of proteins and nanocarriers in rodents and humans.

Authors:  Colin F Greineder; Elizabeth D Hood; Anning Yao; Makan Khoshnejad; Jake S Brenner; Ian H Johnston; Mortimer Poncz; Claudia Gottstein; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2016-02-06       Impact factor: 9.776

3.  Dual-Targeted Theranostic Delivery of miRs Arrests Abdominal Aortic Aneurysm Development.

Authors:  Xiaowei Wang; Amy Kate Searle; Jan David Hohmann; Ao Leo Liu; Meike-Kristin Abraham; Jathushan Palasubramaniam; Bock Lim; Yu Yao; Maria Wallert; Eefang Yu; Yung-Chih Chen; Karlheinz Peter
Journal:  Mol Ther       Date:  2018-02-16       Impact factor: 11.454

4.  Construction and characterization of a truncated tissue factor‑coagulation‑based composite system for selective thrombosis in tumor blood vessels.

Authors:  Peilan Xu; Mingyuan Zou; Shengyu Wang; Tingting Li; Cong Liu; Li Wang; Lanlan Wang; Fanghong Luo; Ting Wu; Jianghua Yan
Journal:  Int J Oncol       Date:  2019-08-12       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.